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Abstract
Resistance to radiotherapy results in relapse and treatment failure in locally advanced esophageal squamous cell
carcinoma (ESCC). High mobility group box 1 (HMGB1) is reported to be associated with the radioresistance in bladder
and breast cancer. However, the role of HMGB1 in the radiotherapy response in ESCC has not been fully elucidated.
Here, we investigated the role of HMGB1 to radioresistance in ESCC clinical samples and cell lines. We found that
HMGB1 expression was associated with tumor recurrence after postoperative radiotherapy in locally advanced ESCC
patients. HMGB1 knockdown in ESCC cells resulted in increased radiosensitivity both in vitro and in vivo. Autophagy
level was found depressed in HMGB1 inhibition cells and activation of autophagy brought back cell’s radioresistance.
Our results demonstrate that HMGB1 activate autophagy and consequently promote radioresistance. HMGB1 may be
used as a predictor of poor response to radiotherapy in ESCC patients. Our finding also highlights the importance of
the utility of HMGB1 in ESCC radiosensitization.
Introduction
Esophageal cancer is the ninth most common malig-
nancy and ranks sixth in cancer deaths worldwide in
20131. Esophageal squamous cell carcinoma (ESCC) is the
major histological subtype of esophageal cancer in China2.
The 5-year overall survival rate of ESCC is 15–25%. For
the patients diagnosed at the locally advanced stage, the
prognosis is even worse3. Preoperative chemoradiotherapy
followed by esophagectomy has become the preferred
approach for locally advanced esophageal cancer based
according to the NCCN guidelines. However, for patients
with ESCC undergoing upfront esophagectomy, the opti-
mal postoperative treatment protocol is controversial.
Several randomized trials showed no survival benefit for
ESCC patients receiving postoperative radiotherapy
(PORT)4,5. Two large trials by Chen6 and Xiao7, on the
other hand, found that PORT significantly improved the
survival of patients with stage III, node-positive ESCC. A
certain subgroup of ESCC patients may be more resistant
to radiotherapy and obtain little benefit from PORT.
However, this group could not be well characterized based
on the current clinical and pathological criteria. Investi-
gating the related biomarker has the potential to help the
clinicians to tailor the treatment plan for individual ESCC
patients. Studying the underlying mechanism may also
help to develop effective drug to increase radiosensitivity
in these patients.
High mobility group box 1 (HMGB1) is a major family
member of injury-related molecules (DAMPs) involving
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in infection, injury and inflammation8. Recently, HMGB1
was reported to be associated with the radioresistance in
bladder cancer9 and breast cancer10. It influences the
tumors’ response of radiotherapy possibly through the
regulating of DNA damage repair pathways, apoptosis and
intracellular autophagy. In ESCC patients, studies have
found that the prognosis is negatively correlated with
HMGB1 expression in tumor tissues and serum sam-
ples11,12. However, the role of HMGB1 in the radiotherapy
response in ESCC has not been fully elucidated.
In this work, we showed that high HMGB1 expression in
tumor tissue is associated with recurrence after PORT for
locally advanced resected ESCC. We further investigated
the function and the mechanism of HMGB1 in radio-
therapy by showing that HMGB1 inhibition increased the
radiosensitivity of ESCC both in vitro and in vivo.
Mechanistically, HMGB1 inhibition induces low autophagy
level, which may contribute to such radiosensitization.
Results
HMGB1 expression associates with recurrence after
postoperative radiotherapy in locally advanced resected
ESCC
We collected in total 120 patients (111 male and 9
female) with locally advanced ESCC. Clinicopathological
factors for the 111 male recruited patients were listed in
Supplementary Table S1. Among the 111 patients, 42 had
in-field recurrence after PORT (37.84%). We examined
the association of tumor HMGB1 expression with in-field
recurrence after PORT which may reflect tumor
radioresistance.
HMGB1 expression in ESCC tissues was measured by
immunohistochemical (IHC) staining (Fig. 1a). Among
the male patients, high HMGB1 expression trended
towards higher in-field recurrence rate (P < 0.0001)
(Fig. 1b). The level of tumor HMGB1 expression in
recurrence male patients was increased (P < 0.0001)
(Fig. 1a, c and Supplementary Fig. S1). The preliminary
result in female patients was consistent with the male
patients (Supplementary Fig. S2). Further Kaplan-Meier
analyses showed that high HMGB1 associated with
shorter relapse-free survival (RFS) (P < 0.0001, Log-rank
test, Fig. 1d), consistent with previous published result11.
Moreover, multivariate analyses revealed that HMGB1
high-expression were independent, unfavorable prog-
nostic indicators for RFS (HR= 3.832, P < 0.001) (Sup-
plementary Table S2). At the same time, we have
conducted the analysis by considering HMGB1 status as a
continues variable (immunoreactivity score, IRS). As
presented by Supplementary Table S3, comparison of
regression results before and after adjustment confirmed
the robust association between tumor HMGB1 expression
and survival. These results suggest that HMGB1
expression is clinically relevant to the in-field recurrence
of locally advanced resected ESCC.
HMGB1 knockdown sensitizes ESCC cells to irradiation
in vitro and in vivo
Based on the result that HMGB1 upregulation was
association with recurrence after radiotherapy, we hypo-
thesized that HMGB1 knockdown would sensitize ESCC
cells to irradiation (IR). To test this, we knocked down
HMGB1 expression in two ESCC cell lines (TE-1 and Eca-
109) with siRNA oligos (siHMGB1) targeting the HMGB1
gene. Cells were then irradiated by X-rays before seeding
on cell culture plates for clonogenic survival assays. The
knock down efficiency of three HMGB1 siRNAs was
tested by real-time polymerase chain reaction (PCR). We
observed highest efficiency for the second siRNA (Sup-
plementary Fig. S3) and used it in the subsequent analysis.
Western blot analysis showed that HMGB1 was success-
fully depleted by siRNA (Fig. 2). Clonogenic survival
assays showed that HMGB1 knockdown ESCC cells were
more sensitive to IR than control (P < 0.05) (Fig. 3a, b).
Detailed radiobiological parameters were shown in
Table 1, which confirmed the results.
To validate whether the influence was applicable in vivo,
we constructed xenograft mouse model using stably
knockdown ESCC cell lines. HMGB1 was stably knocked
down in TE-1 cells via retroviral shRNA constructs. TE-1
cells transfected with shHMGB1 or control shRNA were
used to establish the ESCC subcutaneous Xenograft
mouse model and then the tumor bearing mice were
treated with IR. We observed the significantly inhibited
tumor growth by IR treatment. In comparison, tumors
grew even slower with both IR treatment and HMGB1
depletion in term of tumor weight (P < 0.01) and tumor
volume (P < 0.01) (Fig. 3c–e), indicating the additional
suppressive effect brought by HMGB1 depletion. Toge-
ther with in vitro experiments, these results proved that
HMGB1 knockdown sensitized ESCC cells lines to IR and
that HMGB1 inhibitor might be developed as drug to
increase radiotherapy effect in ESCC patients.
HMGB1 knockdown suppresses the level of autophagy in
ESCC cells
Previous studied reported that endogenous HMGB1 can
regulate autophagy in human pancreatic tumor cell13,
which can protect cells from IR-induced damage14,15. Our
hypothesis was that HMGB1 depletion in ESCC may
increase the ESCC’s radiosensitivity through regulating
autophagy. This hypothesis can be tested into two steps,
first by investigating whether HMGB1 regulates autop-
hagy in ESCC and second, whether such regulation is the
key mechanism of elevated radiosensitivity brought by
HMGB1 inhibition.
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We tested whether HMGB1 regulate autophagy in ESCC
by investigating the level of LC3 II/I in HMGB1 inhibition
ESCC cells. LC3 I and LC3 II are established indicators for
autophagy and LC3 I will be transformed into LC3 II
during autophagy activation16. We observed decreased
LC3 II and elevated LC3 I in siHMGB1-transfected ESCC
cells comparing with control cells, indicating the
decreased autophagy level in HMGB1 inhibition ESCC
(P < 0.05) (Fig. 2). Further fluorescence assay using tandem
fluorescent-tagged LC3 (mRFP-GFP-LC3) also observed
reduced autophagy flux after siHMGB1 transfection in
both TE-1 cells and Eca-109 cells (Fig. 4a). We also
Fig. 1 High HMGB1 expression associates with recurrence and poor outcome after postoperative radiotherapy in locally advanced
resected ESCC. a Representative images of immunohistochemical (IHC) staining of HMGB1 protein in clinical ESCC samples. R, recurrence; NR, non-
recurrence. b Tumor expression of HMGB1 and recurrence rate in clinical ESCC samples, Chi-square test. c Immunoreactivity score (IRS) of HMGB1
protein in clinical ESCC samples, unpaired Mann–Whitney U test. d Kaplan-Meier analyses of RFS for ESCC with high- or low-level tumor expression of
HMGB1, Log-rank test
Fig. 2 HMGB1 knockdown inhibits the autophagy protein expression in ESCC cells. a Western blot was performed to detect LC3 I, LC3 II, and
HMGB1 protein expression in siHMGB1- transfected cells. b Relative protein density according to GAPDH was analyzed by NIH-Image J, t test
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employed transmission electron microscopy (TEM), which
served as another convincible way to classify the autop-
hagosomes inside cells16. TEM images showed that
HMGB1 depleted ESCC cells exhibited fewer autophago-
somes when compared with controls cells (P < 0.05)
(Fig. 4b, c). Together our results showed that HMGB1
knockdown reduced the level of autophagy in ESCC cells.
Activation of autophagy reverses HMGB1-knockdown
induced radiosensitization
Having proved that HMGB1’s regulation of autophagy
in ESCC cells, we then test whether such regulation is the
key mechanism for HMGB1’s impact on radiosensitivity.
We used starvation (Earle’s Balanced Salt Solution, EBSS)
to revert the level of autophagy in siHMGB1-transfected
ESCC cells. We observed elevated autophagy flux (Fig. 5a
and Supplementray Fig. S4), increased LC3 II and
decreased LC3 I expression (P < 0.05) (Fig. 5b, c), as well
as accumulation of autophagosomes (P < 0.05) (Fig. 5d, e)
in siHMGB1–transfected ESCC cells after EBSS treat-
ment, indicating that EBSS successfully recovered the
from autophagy activation.
After confirmation of autophagy recovery, cells were
exposed to various dose of IR treatment. As shown in
Fig. 5f, after EBSS treatment, both cell lines presented
elevated survival rate, indicating the radioresistance
brought by autophagy recovery. Detailed radiobiological
parameters of the cells were shown in Table 1, which
confirmed the results. Intriguingly, the survival rate of
HMGB1 knockdown cells was even higher than controls
after EBSS treatment, suggesting that autophagy has a
strong regulation effect on radiosensitivity of ESCC.
Fig. 3 HMGB1 knockdown sensitizes ESCC cells to irradiation in vitro and in vivo. a Clonogenic survival assays were performed to measure the
radiosensitivity using GraphPad Prism 7.0. b Survival curves of TE-1 or Eca-109 treated with irradiation (IR), t-test. c Representative data of tumors in
nude mice bearing TE-1 cells. d Tumor weight of xenograft mouse tumors, t test. e Tumor volumes of xenograft mouse tumors, t test
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Taken together, our results indicate that siHMGB1
induced radiosensitization is at least partially due to
decreased level of autophagy.
Autophagy level is correlated with expression of HMGB1
and prognosis of ESCC patients
Our cell line-based results showed that inhibiting
HMGB1 can increase ESCC’s radiosensitivity by down-
regulating autophagy. We also investigated the relation-
ship of autophagy status with HMGB1 and
radiosensitivity in clinical samples. Anti-LC3 antibody for
IHC staining was used to indicate the level of autophagy
in clinical samples16. We observed protein expression of
autophagy marker LC3 was positively correlated with
HMGB1 in ESCC tumor tissues (r= 0.642, P < 0.0001)
(Fig. 6a). Concordantly, ESCC patients with in-field
recurrence after PORT had higher tumor LC3 expres-
sion compared with those without recurrence (P < 0.0001)
(Fig. 6b, c). Log-rank test showed that patients with higher
LC3 had a shorter RFS (P < 0.0001) (Fig. 6d).
Discussion
Radiotherapy is the first preferable treatment for ESCC
patients after surgical resection, especially for those in
locally advanced stage. However, many ESCC patients
were resistant to radiotherapy. Identifying the radio-
resistance related biomarker help to tailor the treatment.
Clarifying the molecular mechanism also helped to
develop effective targeted therapies for ESCC patients. In
this study we identified the critical role of HMGB1 in
mediating response to radiotherapy in ESCC. We proved
that HMGB1 in ESCC led to radioresistance through
inducing cytoprotective autophagy.
Previous study reported correlation between HMGB1
expression with the stage and the survival of esophageal
carcinoma11,12. The relationship between HMGB1
expression and survival was also observed in our ESCC
cohort. We proved that HMGB1 is associated with
recurrence of resected ESCC after PORT. Our results are
in good agreement with previous studies in the lower
rectal cancer17 and epithelial ovarian cancer18, that
patients with high-HMGB1 expression were more resis-
tance to chemo and radiotherapy. To the best of our
knowledge, the correlation of HMGB1 expression and
resistance to radiotherapy in ESCC has not been reported
previously. HMGB1 level is expected to be one of the
potential predictors of radiotherapy response.
We observed elevated autophagy protein expression in
clinic samples from radioresistance group, indicating the
activation of autophagy in radioresistance ESCC.
Responsive autophagy is a well-known mechanism that
can protect cells from IR-induced cellular damage19.
Inhibition of autophagy can increase radiosensitivity of
several types of cancer including esophageal carcinoma20.
In addition, Tang’s study clarified that intracellular
HMGB1 activates autophagy by binding to BECN1 and
initiating the formation of autophagosomes13. It is
therefore expected that elevated HMGB1 in ESCC may
protect cells from IR damage by enhancing autophagy.
Indeed, we observed reduced levels of autophagy in
HMGB1-knockdown ESCC cells, accompanied by ele-
vated radiosensitivity. We further proved that the elevated
radiosensitivity could be recovered by inducing autop-
hagy. Correlation between HMGB1 and autophagy, as
well as their association with recurrence and prognosis
were also proved in ESCC clinical samples. Taken toge-
ther, our results suggested that high-expression of
HMGB1 is expected to protect the ESCC’s resistant to
radiotherapy possibly through upregulating the
autophagy.
Table 1 Radiation biologic parameters of ESCC cells in different groups
Cell lines Group D0 (Gy) Dq (Gy) N SF2 (%)
TE-1 Control 3.34 ± 0.24 1.88 ± 0.17 1.76 ± 0.41 72.01 ± 2.50
siHMGB1 2.47 ± 0.31a,* 1.83 ± 0.11a,* 2.10 ± 0.38a, * 69.08 ± 3.70 a,*
siHMGB1+ EBSS 3.55 ± 0.26b,* 2.58 ± 0.21b,* 2.07 ± 0.35b,* 80.11 ± 1.70b,*
EBSS 3.64 ± 0.27 2.81 ± 0.18 2.16 ± 0.37 83.10 ± 1.24
Eca-109 Control 3.18 ± 0.19 1.47 ± 0.31 1.59 ± 0.04 70.32 ± 3.30
siHMGB1 2.48 ± 0.32a,* 1.44 ± 0.19a,* 1.79 ± 0.22a, * 65.71 ± 4.50a,*
siHMGB1+ EBSS 3.88 ± 0.41b,* 2.00 ± 0.23b, * 1.66 ± 0.33b, * 75.11 ± 2.90b,*
EBSS 3.98 ± 0.26 2.38 ± 0.21 1.82 ± 0.39 78.14 ± 1.40
Note: Radiobiological parameters (D0, Dq, N and SF2) were calculated from the single-hit multitarget model (SF= 1−(1−e^ [−kD]) ^N) using GraphPad Prism 7.0
D0: final slope; Dq: quasi-threshold dose; N: extrapolation number; SF2: survival fraction of 2 Gy
*P < 0.05, t test
asiHMGB1 vs. control
bsiHMGB1+ EBSS vs. siHMGB1
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Several issues of the current study should be discussed.
First, the analysis was conducted only in male group due
to low prevalence of ESCC in females and lack of enough
female patients for drawing robust conclusion. With the
project going on, we foresee the increase of our sample
size and expect to expand the analysis to female group.
Second, HMGB1 is known to play compartmental role in
different cellular locations and it regulation upon autop-
hagy was mainly reported in cytosol. It has been shown
that activation of autophagy promotes radioresistance in
multiple type of cancer cells21, while the role of nuclear
HMGB1 in cellular response to irradiation has been little
studied. Our results supported that HMGB1 at least partly
through activating autophagy in cytosol. It will be inter-
esting to also explore the role of nuclear HMGB1 in the
future studies.
In conclusion, our study has shown that HMGB1
expression correlates with recurrence in locally
advanced ESCC after esophagectomy and PORT.
HMGB1 knockdown increased the radiosensitivity of
Fig. 4 HMGB1 knockdown suppresses the level of autophagy in ESCC cells. a ESCC cells stably transfected with mRFP-GFP-LC3 and treated with
siHMGB1. Laser confocal fluorescence microscopy analyses (left) and puncta-based quantification (right) for autophagosomes and autolysosomes
(t test). In the merged image, yellow puncta indicate autophagosomes, while red puncta indicate autolysosomes. b TEM microscopic images of
autophagosomes in TE-1 and Eca-109 transfected with siHMGB1. c Average number of autophagosomes per cell in TE-1 and ECA-109 cells (t test)
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Fig. 5 (See legend on next page.)
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ESCC both in vitro and in vivo through decreased
autophagy. Our investigation supported that high level
of HMGB1 expression in tumors may serve as indicators
for patients who may benefit little from the PORT.
HMGB1 inhibitors may be developed as a combination
therapy to help these patients improve the efficacy of
radiotherapy.
Materials and methods
Patients and clinical specimens
Patients (n= 120) with primary locally advanced but
resectable ESCC between 2010 and 2011 at the 1st or 2nd
Affiliated Hospital of Xi’an Jiaotong University were
recruited. Patients were diagnosed according to the
International Classification of Disease for Oncology 3rd
(see figure on previous page)
Fig. 5 Activation of autophagy reverses radiosensitization induced by HMGB1-knockdown. a ESCC cells stably expressed mRFP-GFP-LC3
protein were transfected with siHMGB1 or treated with starvation (EBSS for 4 h). Laser confocal fluorescence microscopy analyses for
autophagosomes and autophagosomes. In the merged image, yellow puncta indicate autophagosomes, while red puncta indicate autolysosomes.
b Western blot was performed to detect LC3 I, LC3 II, and HMGB1 protein expression in siHMGB1-transfected TE-1 or Eca-109 cells and treated with
starvation (EBSS for 4 h). c Relative protein density according to GAPDH was analyzed by NIH-Image J, t test. d TEM was used to observe the
autophagosomes in siHMGB1-transfected TE-1 or Eca-109 cells and treated with starvation (EBSS for 4 h). e The number of autophagosomes in TE-1
and ECA-109 cells under different conditions. f Survival curves of TE-1 and Eca-109 treated with IR (0, 2,4,6,8 Gy)
Fig. 6 High LC3 expression associates with HMGB1 and poor outcome after postoperative radiotherapy in locally advanced resected ESCC.
a Correlation of HMGB1 and LC3B protein level in clinical ESCC samples. r, Pearson correlation coefficient. b Representative images of IHC staining of
LC3B protein in clinical ESCC samples from patients with/without recurrence. R recurrence; NR non-recurrence. c Statistical analysis of IRS of LC3
protein in clinical ESCC samples, unpaired Mann–Whitney U test. d Kaplan-Meier analyses of RFS for ESCC patients with high-level or low-level tumor
expression of LC3, Log-rank test
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Edition (ICD-O-3). All patients had undergone radical
esophagectomy with lymphadenectomy (R0 resection,
R0= no cancer at resection margins) following with
radiotherapy for 5 weeks (DT: 50 Gy/25 fractions, 2 Gy/
fraction, and 5 fractions/week). No patients had received
preoperative chemo/radiotherapy. ESCC patients com-
bined with other tumors, anastomotic leakage or systemic
infection were excluded. After surgery, staging of the
disease was performed by independent pathologists based
on AJCC 8th22. Patients at pT3N0M0 or pT1-3N+
M0 stage were selected for research. To avoid the
potential confounding from gender, only the male
patients were included for further research. The formalin-
fixed and paraffin-embedded (FFPE) specimens from the
cohort were used for analyzed. The Ethics Committee of
the Health Science Center of Xi’an Jiaotong University
approved the study. Before the study, all patients were
informed and signed informed consent. The study was
conducted in accordance with the provisions of the Hel-
sinki Declaration of 1975.
RFS was evaluated from the date of esophagectomy to
the date of in-field recurrence. In-field recurrence was
defined as tumor recurrence within the 95% isodose line
and was monitored by imaging examination systems and
biopsy.
Cells lines and culture
ESCC cell lines TE-1 and Eca-109 were obtained
directly from Cell Resource Center of Shanghai Institute
of Life Sciences, Chinese Academy of Sciences (Shanghai,
China) and were not cultured for more than 2 months
after receipt. Cells were cultured with RPMI-1640 med-
ium (Thermo Fisher Scientific, Waltham, MA, USA) with
10% fetal bovine serum (FBS) in the 37°C and 5% CO2 cell
incubator. For starvation assays, cells were washed with
phosphate buffered saline (PBS) and then treated with
EBSS (Thermo Fisher Scientific) for 4 h. Considering the
impact of time-relevant difference of EBSS effect, we did
the preliminary time series experiment and determined
that 4 h was appropriate to induce autophagy without
inhibition of cell viability (Supplementary Fig. S5).
Subcutaneous xenograft mouse model
All mouse experiments were conducted according to
the Public Health Service Policy on Humane Care and Use
of Laboratory Animals. Mouse were obtained from and
housed in the Medical Experimental Animal Center (Xi’an
Jiaotong University, China).
To establish the ESCC xenograft model, TE-1 cells (1 ×
107) were injected subcutaneously into the back of each
BALB/c nude mouse (male, 4-week old). To explore the
role of HMGB1 in radiosensitivity in vivo, three groups
were designed: (1) Control shRNA, (2) HMGB1
shRNA, (3) IR plus control shRNA and (4) IR plus
HMGB1 shRNA. The IR groups received 2 Gy X-ray IR by
linear accelerator (Elekta Instruments, Inc., Stockholm,
Sweden) for five consecutive days. The IR treatment was
started nine days after transplantation. The length (a) and
width (b) of the tumor were measured and recorded every
three days and the volume was calculated using the for-
mula V= ab2/2. After 15 days, mice were sacrificed and
tumors were stripped and weighed. The procedures of the
study were approved by the Ethics Committee of the
Health Science Center of Xi’an Jiaotong University.
Western blot
Western blot experiments were performed as previously
described23. Briefly, protein was extracted from cells,
electrophoresed in 15% SDS gel, and then transferred to
PVDF membranes. After blocked, the membranes were
incubated with primary antibodies (anti-HMGB1, 1:1000,
Abcam, Cambridge, UK; anti-LC3, 1:1000, Abcam) over-
night and secondary antibodies for 2 h. The signal was
detected by ECL Kit (Millipore, MA, USA) and the final
scanned images were analyzed using NIH-Image J.
Clonogenic survival assay to test cells’ radiosensitivity
Clonogenic survival assay were performed as previously
described24. Cells were incubated into six-well plates and
were irradiated at a dose of 0-8 Gy. 14 days after IR, cells
were fixed and stained, and clones were counted. Cell
survival fraction (SF) was calculated and substituted into
the single-hit multitarget model: SF= 1–(1–e^ [−kD])^N.
Cell survival curves were then generated using GraphPad
Prism 7.0 and radiobiological parameters (D0, Dq, N, and
SF2) were calculated.
IHC staining analysis of clinical ESCC specimens
FFPE specimens were sectioned 4.5 μm thick and placed
in xylene for dewaxing. Specimens were then hydrated by
gradient ethanol gradient and placed in citrate buffer for
antigen retrieval. After blocked, primary antibodies (anti-
HMGB1, 1: 1000, Abcam; anti-LC3, 1:500, Abcam) were
incubated overnight. Secondary antibodies were incu-
bated for 1 h and then horseradish peroxidase was added
dropwise to perform DAB staining. After soaking in 50%
hematoxylin for 6 min, specimens were dehydrated by
gradient ethanol, transparented by xylene and mounted
with coverslips using mounting medium.
IHC staining was assessed using a light microscope by
two independent pathologists on each tissue section
according to the IRS established by Remmele and
Stegner25. ESCC specimens staining was assessed by using
staining of the normal esophageal epithelial cells as
internal control. IRS combines a score for staining
intensity from 0–3 (0, no color reaction; 1, mild; 2,
moderate; 3, intense) multiplied with the score for the
percentage of positive cells from 0–4 (0, no positive cells;
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1, <10%; 2, 10–50%; 3, 51–80%; 4, >80%). The level of
protein expression was identified as low-expression (IRS
< 6) and high-expression (IRS ≥ 6) based on the IRS.
siRNA transfection
HMGB1 siRNA (siHMGB1 group) and scrambled
siRNA (control group) were purchased from Gene
Pharma (Shanghai, China). Cells were transfected with
siRNA using Micropoly-transfecterTM Tissue Reagent
(Micropoly, Nantong, China) according to the manu-
facturers’ instruction. Six hour later, cells were washed
with PBS and cultured with complete medium in the
incubator for 48 h.
shRNA adenovirus infection
HMGB1 shRNA (shHMGB1 group) and scrambled
shRNA (control group) were purchased from Hanheng
Biotechnology (Hanheng Biotechnology Co., Ltd.,
Shanghai, China). Cells were plated into six-well plates
and infected with shRNA adenovirus according to the
manufacturer’s instructions. Six hour later, cells were
washed with PBS and cultured with complete medium in
the incubator for 48 h.
Transmission electron microscopic inspection
Cells were fixed with the Electron Microscope Fixative
(Servicebio Technology CO., LTD, Wuhan, China) for 2 h.
The fixed samples were dehydrated with a series of
acetone, embedded and solidified. Ultrathin sections (50
nm) were prepared and carefully placed on the support
membrane. The intracellular structures were observed
using TEM HT7700 (Hitachi, Tokyo, Japan).
Autophagy flux monitor
The mRFP-GFP-LC3 adenovirus vectors were used to
monitor autophagy flux (Hanheng Biotechnology Co.,
Ltd., Shanghai, China). LC3 is tracked by red mRFP and
green GFP, while GFP is sensitive to acidity. When lyso-
somes and autophagosomes were fused into autolyso-
somes, the signal of GFP fluorescence quenching and
mRFP fluorescence remained unchanged. Therefore, the
red signal indicates autolysosomes and the yellow signal
indicates autophagosomes.
Cells were seeded in a 35-mm laser confocal culture
dish and mRFP-GFP-LC3 adenovirus was infected
according to the manufacturer’s instructions. 6 h later,
cells were washed with PBS and cultured with complete
medium in the incubator for 48 h. Laser confocal fluor-
escence microscopy IX83 (Olympus, Tokyo, Japan) was
used to observe the autophagy flux and LC3 puncta.
Statistical analysis
Measurement data between two groups were compared
by Mann–Whitney U test or t test where appropriate. The
correlation between HMGB1 expression and recurrence
rate was performed using the Chi-square test. Log-rank
test was used to determine the significance of Kaplan-
Meier curves. To eliminate the confounding effect, uni-
variable Cox proportional hazard model and logistic
regression were used to filter for associated factors of RFS.
Then multivariable Cox proportional hazard model and
logistic regression were used to analyze association
between HMGB1 expression and RFS adjusting for age,
tumor location, histology grade and pTN stage. Statistical
analysis software SPSS 20.0 (SPSS, Inc., IL, USA) and
GraphPad Prism 7.0 (GraphPad Software, Inc., CA, USA)
were used. All data were presented as mean ± SEM of
three or more experiments. P < 0.05 was considered sta-
tistically significant.
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